Continuous Glucose Monitoring Market Size, Growth Rate and Forecast to 2034: Drivers, Risks and Regional Split

Continuous glucose monitoring has moved from a niche device category to a market with a clear growth record. This analysis draws on CDI's continuous glucose monitoring market report and sets out the size, the rate, the pressure points and the geography.

The continuous glucose monitoring market was worth USD 12.8 billion in 2025. The forecast takes it to USD 36 billion in 2034, a compound annual growth rate of 11.47% across the 2026 to 2034 forecast period.

The historical series matters as much as the forecast. The market stood at USD 4.3 billion in 2020 and USD 10.7 billion in 2024, before reaching USD 12.8 billion in 2025. Growth over that stretch compounded at 24.37% before the forecast period begins. The forecast rate of 11.47% is therefore lower than the rate already recorded, and it is applied flat across the whole period instead of being ramped through it.

That framing is useful for anyone testing the forecast. A reader who expects the market to cool as it matures will find that assumption already built in. The forecast does not require the 2020 to 2024 pace to continue; it requires roughly half of it.

The historical period runs 2020 to 2024, the base year is 2025, and the report covers North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.

Three features of the data explain the growth rate: the trend already in the record, the weight of the two largest regions, and the pace of one component line.

The component line is the sharpest. Software and Data Platforms compounds at 17.8% against 11.47% for the market. It rises from USD 1.536 billion in 2025 to USD 7.2 billion in 2034, and from 12% of revenue to 20%. At the other end of the component axis the rate is 5.7%. The spread between those two figures decides whether the market's 11.47% holds, so position on the component axis is a growth decision, not a product one.

The regional driver is concentration. North America is the largest region at USD 5.76 billion in 2025, or 45% of global revenue, and reaches USD 14.04 billion by 2034 while holding 39%. Europe follows at 24% and USD 3.072 billion, reaching USD 8.28 billion. The two regions account for the majority of both the 2025 base and the revenue added by 2034. A regional plan that treats all five regions at equal weight misreads where the growth lands.

The same pattern appears in adjacent categories. The remote patient monitoring market is forecast to reach USD 70.8 billion by 2034 at a CAGR of 11.3%, and glucose monitoring devices hold 20% of its product type axis. Its leading region is also North America, at 41% of global revenue through 2034. Connected glucose data and broader remote monitoring programmes draw on the same buyers and the same reimbursement systems.

Software shows up as the fast line in other diagnostics categories too. In the immunoassay market, Software & Services compounds at 9.2% against 6.82% for the market, rising from USD 3.02 billion in 2025 to USD 6.71 billion in 2034. The scale differs, but the direction matches: the data layer grows faster than the hardware it sits on.

The report's bear case is USD 26 billion in 2034, against USD 36 billion in the base case. Neither case changes the USD 12.8 billion 2025 base. The downside rests on one stated assumption with three parts:

• Coverage expansion stalls.
• Tender pricing cuts net price per sensor faster than volume grows.
• A sensor safety action or supply interruption slows adoption in the largest markets.

Each of these acts on a different part of the market. Coverage decisions are made by public and private payers. Tender pricing is a procurement matter. A safety action or supply interruption is an operational event at a single manufacturer or product line, and it would be felt where volumes are highest.

Two structural features sharpen the exposure. The first is the weight of Sensors. The component carries 52% of 2025 revenue at USD 6.656 billion, but it compounds at 11% against 11.47% for the market. Its share falls to 50% by 2034 even as its revenue rises to USD 18 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it. The market's forecast is, to a large extent, a forecast for one component line.

The second is the weight of one country. The United States is 88.54% of North America, at USD 5.1 billion against the region's USD 5.76 billion in 2025, and USD 12.4 billion by 2034. Read as a region, North America looks diversified. Read by weight, it is not, and the regional forecast inherits whatever happens in that one market.

The upside case deserves equal attention. If large public and private payers extend coverage to most people with Type 2 diabetes, over-the-counter sales grow quickly, and longer-wear sensors lower cost per day enough to widen use in lower-income markets, the market reaches USD 41 billion by 2034. The base is the same USD 12.8 billion in 2025. The range from USD 26 billion to USD 41 billion is set mostly by reimbursement and pricing decisions.

By region, North America holds 45% of global revenue in the base year and Europe 24%. Asia Pacific holds 22%, Latin America 4.5% and the Middle East and Africa 4.5%. North America remains the leading region through 2034, with 45% of global revenue stated for the forecast horizon in the report's headline, and its share is 39% in the final year in the regional detail. Europe's revenue reaches USD 8.28 billion by 2034.

By component, the 2025 shares are:

• Sensors: 52%
• Insertion and Accessories: 16%
• Transmitters: 12%
• Software and Data Platforms: 12%
• Receivers and Readers: 8%

Sensors is the largest line by a wide margin, and Software and Data Platforms is the line that gains share, moving from 12% to 20%. It is the place on the component axis where share changes hands at scale. That makes it the point at which an entrant can take position without displacing the incumbent in Sensors.

The report segments the market on nine further axes beyond component, including product type, sensor wear duration, sensing technology, application, age group, connectivity and integration, end user, distribution channel and reimbursement status. The wear duration, sensing technology and reimbursement axes map directly onto the upside and downside assumptions above, which is why they repay attention for anyone building a scenario of their own.

For a full reading of the forecast, the segmentation and the scenarios, see the continuous glucose monitoring market report.